Combining COVID-19 BA4/5 and Influenza mRNA

Peter A. McCullough

Recently, both Pfizer and Moderna announced they were developing a combination injection utilizing mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus. Because the COVID-19 component is under Emergency Use Authorization plus questionable unorthodox licensure meant to provide the legal basis for a system of vast mandates, limited animal studies plus no completed human trial data to date, that component should be off the table from the start.

Latest articles

The Goddard Report A podcast with Dr. Stephen Malthouse on “Making Doctors... All previous outbreaks, epidemics and pandemics end when Community Immunity, NOT...
Amanuensis Variants have been one of the hallmarks of this pandemic, with...
Samuel Reinfeld et al. The COVID-19 pandemic continues to have a deleterious...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!